Mounjaro NHS Criteria UK: Who Qualifies (October 2026)

01 · The core answer

What are the NHS criteria for Mounjaro?

The NHS criteria for Mounjaro start with BMI and health conditions. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ That is the destination of the rollout, not where every area is today.

The rollout is the part most people miss. Mounjaro is available on the NHS, but access is being phased in over several years. The NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁴

So the honest answer has layers. Meeting the recommendation means you are within the group NICE wants to treat. Whether your practice can offer it now depends on which phase your local NHS has reached and where you sit in the priority order. If you want a more detailed walk-through of how those phases unfold, our week-by-week NHS timeline guide covers it, and our page on who is eligible for NHS Mounjaro looks at the same question from the patient side.

02 · Your next step

Do you meet the criteria, and what should you do?

Work out your BMI first, then list any weight-related conditions your doctor has already diagnosed. The ones named in the licence include high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes.¹ Bring those details to your GP practice and ask directly where your area is in the rollout and which priority group you fall into.

If you are within the NICE recommendation but your practice is not yet offering treatment, you have a decision. You can wait for your phase to open, or you can look at regulated private treatment. Our guide to getting Mounjaro on the NHS in the UK sets out how to approach that conversation.

If your BMI is below the NHS threshold but within the licence, the NHS is unlikely to be your route now. The licensed range is wider than the NHS recommendation, and a prescriber assesses your BMI, medical history and current medicines before deciding whether it is suitable.¹ Our private Mounjaro criteria page explains that assessment. When you are ready, the Mounjaro pen page shows current doses, with a standard starting pen at £169.99 per month (prices checked 25 October 2026). New customers save £40 on a first order with code FIRST40.

Whichever route you choose, treatment is used alongside a reduced-calorie diet and increased physical activity, and individual results vary. You can read more on our weight loss clinic page.

03 · Criteria in plain English

The NHS criteria in plain English

The NICE recommendation is built on two things: your BMI and whether you live with a weight-related health condition. NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ Both parts matter. A high BMI alone does not complete the picture, and a health condition alone does not either.

BMI is your weight in kilograms divided by your height in metres squared, which is why it is written in kg/m². It is a screening measure rather than a verdict on your health, but clinical guidance uses it because it is consistent and easy to check. Your GP practice will normally already hold a recent measurement, or can take one.

Weight-related conditions are medical problems that are more likely, or harder to manage, at a higher body weight. Examples given in the licence include high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes.¹ These need to be diagnosed by a clinician, not self-assessed, so a recorded diagnosis in your notes is what counts.

People often ask for a fixed short checklist of criteria. In reality there is no tidy list that applies identically everywhere, because the national recommendation sits alongside a phased rollout. What stays constant is the logic: a qualifying BMI, a qualifying condition or conditions, and the priority group your local NHS is currently treating.

That priority element is why two people with the same BMI can get different answers. The NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶ Someone at the very top of that need list is seen before someone who meets the recommendation but sits later in the order.

Treatment is also never a standalone fix. It is used alongside a reduced-calorie diet and increased physical activity.¹ Clinicians looking at your eligibility will usually want to talk about those parts of your care as well, so it helps to go in ready to discuss what you currently eat, how active you are and what you have already tried.

Finally, being within the criteria is not the same as being suitable. Your clinician will still look at your medical history and current medicines, and some people are advised against the medicine. For a related, plainer overview, see our page on the NHS GLP-1 criteria, and for the same question phrased by injection type, criteria for weight loss injections on the NHS.

04 · How the phased rollout works

How the phased NHS rollout works

The rollout is phased because demand for treatment is far larger than a health service can supply at once. Mounjaro is available on the NHS, but access is being phased in over several years.⁶ This is a deliberate national approach, not a local failure or an oversight.

In practice, phasing means NHS England decides which groups are offered treatment first, and local teams work through those groups in order. The NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶ The starting group is therefore narrower than the NICE recommendation, which reaches people with a BMI of at least 35 and at least one weight-related condition.⁴

The practical effect is a gap between what you may qualify for in principle and what your practice can prescribe now. A person with a BMI of 36 and a single condition is inside the NICE recommendation yet, at the start of the rollout, is outside the first priority group. As the rollout widens, that person moves closer to being offered treatment.

The reliable approach is to ask your GP practice or integrated care board where they are in the phasing, because local capacity can differ.

Full rollout is expected to take years.⁴ That is the key planning fact. If you meet the NICE recommendation but not the earliest group, you are not being refused for good. You are in a queue whose length is set by national phasing and local capacity.

While you wait, your clinician can still support you with the other parts of weight management. Nutrition, physical activity, sleep, and managing the conditions that are already diagnosed all continue to matter, and they are the same things that treatment works alongside.

It is also worth separating the rollout from the licence. The licence describes who a prescriber may legally treat; the NHS rollout describes who the NHS is currently funding and in what order. That is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁴ Our related page on NHS Mounjaro criteria for 2026 tracks the same topic by year.

05 · Ethnic background adjustment

The ethnic-background BMI adjustment

The BMI threshold is lowered for some ethnic backgrounds because health risk does not track BMI identically across populations. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight-related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.⁴

In practice this means the threshold you compare yourself against is lower if you belong to one of those groups. The NICE recommendation of a BMI of at least 35 becomes a slightly lower figure, and the same logic applies to the higher thresholds used in the early phases of the rollout.

If you think this applies to you, say so when you speak to your GP practice. Do not assume it will be applied automatically. Clinicians work through a lot of information in a short appointment, and stating your background and asking whether the adjusted threshold applies is entirely reasonable.

The adjustment matters in both directions of the pathway. It can bring you into the NICE recommendation at a lower BMI, and it can bring you into an earlier rollout group than the headline figure suggests. Ask about both.

The same principle is built into private prescribing. A prescriber assessing you privately looks at your BMI, medical history and current medicines together, and your background is part of the clinical picture they consider.¹

It is also worth being clear about what the adjustment is not. It is not a loophole, and it does not change the requirement for a weight-related condition where one applies. It is a recognition that risk shows up earlier in some groups, and it simply moves the starting line accordingly.

If you have questions about how treatment might suit you specifically, your prescriber is the right person to ask, and you can raise it in the free consultation.

Finally, keep your own records. Note your height, weight, the date of your last measurement and the conditions on your record. Having them to hand makes any conversation about thresholds quicker and more accurate, whichever route you take. Our page on how people qualify for NHS Mounjaro adds more on what to prepare.

06 · NHS versus private criteria

NHS versus private criteria compared

The private licence is wider than the NHS recommendation. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.¹ The NICE recommendation, by contrast, is for a BMI of at least 35 plus at least one weight-related condition.⁴

These are different questions. The licence answers who a prescriber may lawfully treat with the medicine. The NICE recommendation answers who the NHS has agreed to fund. A person can be perfectly suitable under the licence and still outside what the NHS is currently funding for them.

Someone with a BMI of 31 and no other conditions meets the licensed threshold of 30 or above but not the NHS threshold of 35. Someone with a BMI of 29 and high blood pressure meets the licence through the lower band but is not within the NHS recommendation at all. Neither of them is being treated unfairly; they are simply being measured against different yardsticks.

Private treatment still requires a full clinical assessment. A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹ It is not an automatic yes, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

The way the two routes feel also differs. The NHS route depends on your priority group and local capacity. The private route depends on suitability and on cost. Our standard 2.5mg starting pen is £169.99 per month, and at standard prices before discounts a first year costs £2,399.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,279.88 if you step up through every dose to 15mg. A new customer's first order is £40 less, and every later order is £25 less.

Cost is a real consideration, and we would rather you weigh it honestly than feel pushed. If the NHS is likely to treat you in a reasonable time and you are comfortable waiting, that may be the right choice. If not, private treatment is a legitimate alternative.

Neither route removes the need for lifestyle changes. Treatment is used alongside a reduced-calorie diet and increased physical activity in both cases. You can see how we compare in our related guide to criteria for weight loss medication on the NHS.

07 · Who should not take it

Who should not take Mounjaro

Meeting a BMI threshold is not enough on its own, because Mounjaro is not suitable for everyone. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive.¹³ Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. These are firm exclusions, and they apply whether you are treated through the NHS or privately.

Other conditions call for extra care. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹³

There is also a precaution about the thyroid. In rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials.¹ As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2, because they will weigh this in your assessment. Routine thyroid monitoring is not required for most people.

Share your full medical history and medicine list during consultation. That includes prescription medicines, anything you buy over the counter, and supplements. A missing detail can change the advice you are given, so completeness matters more than speed.

Contraception is a specific point. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed, so your prescriber will talk this through if it applies to you.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ If you take insulin or sulfonylureas, doses may need adjusting because of the risk of low blood sugar, so tell your prescriber about them.

Many readers also ask about side effects. Like all medicines, Mounjaro can cause side effects, and most are digestive. The most common — affecting more than 1 in 10 people — are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. Side effects are most likely when starting treatment or moving up a dose, and for most people they ease within days to a few weeks as the body adjusts.¹³ Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. Report any suspected side effect through the Yellow Card scheme.¹⁹

A symptom that is not on the leaflet list is not a listed side effect — tell your prescriber about any new or lasting symptom.

08 · What treatment achieves

What the trial results show

Eligibility criteria exist because the medicine works well enough in the right group to justify the cost and the monitoring. The main trial behind the weight-management licence is SURMOUNT-1. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages, and individual results vary. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² Trial averages do not predict your own result, so treat them as a picture of what is possible rather than a promise.

The same trial reports how many people reached certain milestones. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.² Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

To make a percentage tangible, take a worked example. For someone starting at 100 kg, 20.9% is about 21 kg. That is straight arithmetic from the trial average, not a forecast for you.

Why does this matter for criteria? Clinical thresholds target people for whom a meaningful reduction in body weight is likely to lower the risk of weight-related conditions. A higher BMI with existing conditions is where that benefit is judged to be greatest, which is why the NHS rollout began with the highest-need groups first.

It also helps to understand what these numbers do not show. They do not show how the medicine performs when the diet and activity element is skipped. They do not show your personal response. And they are not a comparison with other medicines, because each trial had its own design and participants.

Keep expectations grounded. The point of treatment is to support a reduced-calorie diet by helping you feel fuller sooner and less hungry between meals.

09 · How the medicine works

How Mounjaro works and how it is taken

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.

That dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy and Ozempic). Ozempic is semaglutide licensed for type 2 diabetes — it is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label. The licensed weight-management options are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg).

Your prescriber decides where you settle: the dose steps up after at least 4 weeks on each dose, depending on how you respond and tolerate it.

A point people often ask about is stopping. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system.¹ There is no way to speed this up, and nothing needs doing while it clears.

Storage is simple. Keep unopened pens in the fridge at 2–8°C until first use, and they keep until the printed expiry date. Once in use, a pen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Do not use a pen that has been above 30°C or has been frozen.¹³ Follow the pen's own instructions for the injection itself.

Every order from us includes needles, a sharps bin and injection guidance. The way tirzepatide fits into a routine is deliberately straightforward: a once-weekly injection, ongoing monthly reviews and follow-up assessments by the prescribing team, with side-effect support if you need it.

Beware of products sold as a cheap stand-in. Low-cost supplements marketed with dramatic weight-loss claims carry no clinical oversight, and sellers offering to supply a prescription medicine without a consultation or prescription are a safety risk. Report counterfeit concerns to the MHRA.⁷

10 · Private route and ordering

If you do not qualify yet: the private route

If you are outside the current NHS group, regulated private treatment is the alternative, and it follows a clear process. EverydayMeds is a GPhC-registered UK online pharmacy (GPhC 9012878) supplying genuine KwikPens through official LillyDirect supply, with all six doses in stock.

The journey has a few stages. You complete a free online consultation, which is a short health questionnaire with no charge and no obligation. It is then reviewed by a GPhC-registered prescriber rather than a scoring script; payment is taken when you place the order, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

Once approved, your order is dispensed by our registered pharmacy. Same-day dispatch applies when ordered by 3pm, and delivery is free, next-day, tracked and in temperature-controlled, discreet packaging. Saturday delivery is £14.99.

On cost, your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99). Switching from another provider at 15mg? Your first order is £259.99. After that, an automatic £25 reorder discount applies to every future order (code DOSE25). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £879.96 at standard prices, before discounts. Prices checked 25 October 2026.

The price shown is the price paid, with no hidden fees, and the consultation is free. You can pay by Visa or Mastercard, use Klarna, or choose pay-monthly options. There are no subscriptions, and repeat orders re-check suitability rather than auto-shipping.

Support does not stop at dispatch. Ongoing monthly reviews, dose titration and follow-up assessments are handled by the prescribing team, and our free GLPTrackr companion app helps you track your journey. Over 100,000 customers have been supported by us, which is a measure of the people we have served rather than a claim about results.

You do not have to choose forever. Some people use private treatment while waiting for their NHS phase, then discuss the transition with their GP. If you are weighing it up, the Mounjaro pen page has live prices and the consultation, and our private criteria explainer sets out what the prescriber will look at. Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. Individual results vary, and this page is information, not a substitute for medical advice.